We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · August 19, 2020

Bevacizumab Plus mFOLFOX6 vs mFOLFOX6 Alone as First-Line Treatment for RAS-Mutant Unresectable Colorectal Liver-Limited Metastases

Journal of Clinical Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
Bevacizumab Plus mFOLFOX6 Versus mFOLFOX6 Alone as First-Line Treatment for RAS Mutant Unresectable Colorectal Liver-Limited Metastases: The BECOME Randomized Controlled Trial
J. Clin. Oncol 2020 Aug 04;[EPub Ahead of Print], W Tang, L Ren, Q Ye, Y Wei, G He, Q Lin, X Wang, M Wang, F Liang, Y Cui, T Liu, J Xu

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading